Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 22, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04704505
View directory record Official record
Conditions
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
Interventions
radium-223, Bipolar Androgen Therapy (BAT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT06330805
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Contrast Agent, Leuprolide, Magnetic Resonance Imaging, Physical Performance Testing, Relugolix
Procedure · Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA

NCT04760483
View directory record Official record
Conditions
Male Urogenital Diseases, Genital Diseases, Male, Prostatic Disease, Prostatic Hyperplasia
Interventions
SoracteLite(TM) TPLA for BPH
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 22, 2026, 4:12 PM EDT
Terminated No phase listed Observational

Transrectal Photoacoustic Imaging of the Prostate

NCT02365883
View directory record Official record
Conditions
Prostate Cancer
Interventions
Photoacoustic Imaging System
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 22, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00006002
View directory record Official record
Conditions
Prostate Cancer
Interventions
dexamethasone, semaxanib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
18
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 4:12 PM EDT
Active, not recruiting Phase 1 Interventional

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT03860272
View directory record Official record
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Terminated No phase listed Observational

Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy

NCT05872503
View directory record Official record
Conditions
Prostate Specific Antigens, Positive Digital Rectal Examination, Strong Family History of Prostate Cancer, Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years to 120 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 22, 2026, 4:12 PM EDT
Active, not recruiting Phase 2 Interventional

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

NCT02881242
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib
Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 22, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

NCT04009083
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care MRI, Fluciclovine PET scan added to MRI
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 22, 2026, 4:12 PM EDT
Suspended Not applicable Interventional

Catheterless Water Vapor Therapy for the Treatment of BPH

NCT04997369
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Rezum
Device
Lead sponsor
Northwell Health
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 22, 2026, 4:12 PM EDT
Completed No phase listed Observational

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 22, 2026, 4:12 PM EDT
Completed No phase listed Observational

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

NCT03535987
View directory record Official record
Conditions
Prostate Cancer
Interventions
myocardial PET imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
51 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 22, 2026, 4:12 PM EDT
Terminated No phase listed Observational

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy

NCT04234399
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Fluciclovine PET/CT using a digital PET/CT
Diagnostic Test
Lead sponsor
University of Vermont
Other
Eligibility
40 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 22, 2026, 4:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 22, 2026, 4:12 PM EDT
Not listed No phase listed Observational

PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy

NCT00966095
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Source MDx
Industry
Eligibility
40 Years and older · Male only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
San Bernardino, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Oct 22, 2026, 4:12 PM EDT
Active, not recruiting Not applicable Interventional

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Disease
Interventions
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
Behavioral · Drug
Lead sponsor
McMaster University
Other
Eligibility
45 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
4
States / cities
Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Recruiting Phase 3 Interventional

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

NCT07711002
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
42
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00736645
View directory record Official record
Conditions
Prostate Cancer
Interventions
selenomethionine, finasteride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 22, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model

NCT02451345
View directory record Official record
Conditions
Prostate Cancer
Interventions
Personalized risk model+website+coaching intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 22, 2026, 4:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastasis
Interventions
Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide, Rescue Medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

NCT02047253
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Carfilzomib, Dexamethasone, Acyclovir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Macon, Georgia • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 4:12 PM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

NCT00003343
View directory record Official record
Conditions
Prostate Cancer
Interventions
endocrine-modulating drug therapy, mitoxantrone hydrochloride, prednisone, prinomastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 22, 2026, 4:12 PM EDT